Delivery Order SPE2DP20D0002-SPE2DP25F109U
Award Date 9/8/25
Potential Completion Date 9/23/25
Potential Value $330K
Federal Agency
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Parsippany, NJ 07054, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The U.S. Department of Defense's Medical Supply Chain awarded a delivery order valued at $660,627.72 to Teva Pharmaceuticals USA, Inc. for Adenovirus Type 4 vaccine on August 12, 2025, with an ultimate completion date of August 26, 2025. This firm-fixed-price delivery order, issued without set-aside designation, represents continued federal procurement from Teva as a critical supplier of vaccines and pharmaceutical products to military immunization programs. The contract will be performed at...
- The U.S. Department of Defense Medical Supply Chain awarded a delivery order valued at $825,784.65 to Teva Pharmaceuticals USA, Inc. for Adenovirus Type 4 vaccine on September 8, 2025, with an ultimate completion date of September 23, 2025. The contract is structured as a firm fixed-price delivery order with no set-aside designation, and performance will be executed at Teva's facility in Parsippany, New Jersey. This delivery order is issued under a larger indefinite delivery vehicle and...
- The U.S. Department of Defense's Medical Supply Chain awarded a $660,627.72 firm-fixed-price delivery order to Teva Pharmaceuticals USA, Inc. on September 8, 2025, for the supply of Adenovirus Type 4 vaccine. The contract, issued without set-aside designation, is scheduled for completion by September 23, 2025, with performance conducted at Teva's facility in Parsippany, New Jersey. This delivery order represents a continuation of Teva's established role as a critical supplier of the Adenovirus...
- The Defense Logistics Agency awarded Teva Pharmaceuticals USA, Inc. a firm fixed-price delivery order valued at $165,156.93 for Adenovirus Type 4 vaccine with an ultimate completion date of September 23, 2025. The contract, issued without a set-aside designation, is being performed in Parsippany, New Jersey, where Teva maintains its U.S. headquarters. This delivery order supports the Department of Defense's immunization programs and represents part of Teva's established role as a critical...
- The U.S. Department of Defense's Medical Supply Chain division awarded a $1.16M firm fixed-price delivery order to Teva Pharmaceuticals USA, Inc. for Adenovirus Type 4 vaccine, with an ultimate completion date of August 26, 2025. The contract, which carries no set-aside designation, will be performed at Teva's manufacturing facility in Parsippany, New Jersey. This delivery order represents a continuation of Teva's established role as a critical supplier of vaccines and pharmaceutical products to...
- Teva Pharmaceuticals USA, Inc., headquartered in Parsippany, New Jersey, was awarded a delivery order valued at $825,784.65 for Adenovirus Type 4 vaccine on September 8, 2025, with an ultimate completion date of September 23, 2025. This firm-fixed-price contract, issued without a set-aside designation, supports the Medical Supply Chain within the Department of Defense. The delivery order represents a continuation of Teva's established role as a critical supplier of the Adenovirus Type 4...
- Teva Pharmaceuticals USA, Inc. has been awarded a $1,526,969 firm fixed price delivery order from the Defense Logistics Agency Troop Support Medical to supply adenovirus type 4 vaccine. This delivery order was issued under an existing contract vehicle and will support the immunization programs of the military. Teva will deliver the vaccine products to the agency's location in Parsippany, New Jersey by December 19, 2023. As a major pharmaceutical manufacturer, Teva has extensive experience...
- Teva Pharmaceuticals USA, Inc. has been awarded a $305,393.76 firm fixed price delivery order from the Defense Logistics Agency Troop Support Medical to provide adenovirus type 4 vaccine. Performance will take place in Parsippany, New Jersey through December 2023. This delivery order was issued against an existing contract vehicle and supports the immunization programs of the military. Teva Pharmaceuticals has a history of partnering with subcontractors and receiving contract awards to supply...
- Teva Pharmaceuticals USA, Inc. has been awarded a $916,181 firm fixed price delivery order from the Defense Logistics Agency Troop Support Medical to supply adenovirus type 4 vaccine. The delivery order was awarded on December 14, 2023 and is to be completed by December 19, 2023. Teva will provide the vaccine from its Parsippany, New Jersey location to support immunization programs of the Defense Logistics Agency Troop Support Medical. As the prime contractor, Teva has extensive experience...
- The U.S. Defense Logistics Agency Troop Support Medical awarded a Firm Fixed Price Delivery Order contract to Teva Pharmaceuticals USA, Inc. for the delivery of Adenovirus Type 4 vaccines. The $135,747.00 contract has an August 25, 2020 completion date. Teva Pharmaceuticals USA, Inc. is a foreign-owned, for-profit manufacturer that has provided a range of pharmaceutical products, including vaccines, antiviral medications, and respiratory treatments, to federal customers such as the Department of...